Donate For Public and Patients Store Search

F042 - So Many Biologics, So Little Time: How to Pick Your Poison in an Era of Biologic Overload

Friday, March 1; 3:30 PM - 5:30 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Identify the appropriate biologic for treating psoriasis tailored to the individual patient
  • Determine what aspects of patient history and comorbidities to focus on when considering treatments for psoriasis
  • Evaluate the current landscape of biologics for psoriasis, taking into account non-biologic therapy and treatments in the pipeline

Description

In the current landscape of psoriasis treatments, many biologic treatments are available. Among different classes, multiple agents often exist with subtle differences in efficacy, mechanism of action, and side effect profile. This forum is intended to help the clinician decide on an appropriate treatment for psoriasis, encompassing topics including when it is better not to use a biologic, which medication is most efficacious, comorbidities to consider, and psoriatic arthritis. The pipeline for biologics will also be presented so that attendees can appreciate what is on the horizon. Finally, an interactive session will wrap up the forum comprised of challenging cases.

Disclosures

  • Callis-Duffin, Kristina Patrice, MD: AbbVie – C(H), I(Grants/Research Funding), SP(H); Amgen – A(H), C(H); Bristol-Myers Squibb – C(Fees); Celgene Corporation – A(H), I(Grants/Research Funding); Eli Lilly and Company – C(H), I(Grants/Research Funding); Janssen Pharmaceuticals, Inc – A(H), I(Grants/Research Funding); Novartis – C(H), I(Grants/Research Funding); Pfizer Inc. – C(H), I(Grants/Research Funding); Sienna Biopharmaceuticals – C(H), I(Grants/Research Funding);
  • Cohen, Russell W., MD: AbbVie – SP(Fees); Celgene – SP(Fees); Eli Lilly and Company – SP(Fees); Janssen Pharmaceuticals, Inc – SP(Fees); Novartis – SP(Fees); Ortho Dermatologics – SP(Fees); Pfizer Inc. – SP(Fees); Regeneron Pharmaceuticals, Inc. – SP(Fees); Sanofi Genzyme – SP(Fees); Sun Pharmaceutical Industries Ltd. – SP(Fees); UCB – SP(Fees);
  • Gordon, Kenneth B., MD: AbbVie – C(H), I(Grants/Research Funding); Almirall – C(H); Amgen – C(H), I(Grants/Research Funding); Boehringer Ingelheim – C(H), I(Grants/Research Funding); Bristol-Myers Squibb – C(H); Celgene Corporation – A(H), I(Grants/Research Funding); Demira – C(H); Dermavant Sciences – C(H); Eli Lilly and Company – I(Grants/Research Funding); Janssen Pharmaceuticals, Inc – A(H), I(Grants/Research Funding); Kyowa Hakko Kirin Pharma, Inc. – C(H); Leo Pharma Inc – C(H); Lilly ICOS LLC – A(H); Novartis – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – A(H); Othro Dermatologics – C(H); Pfizer Inc. – A(H); Sun Pharmaceutical Industries Ltd. – C(H); UCB – C(H);
  • Han, George, MD, PhD: Celgene – I(Grants/Research Funding); Eli Lilly and Company – I(Grants/Research Funding); Janssen Pharmaceuticals, Inc – A(H), I(Grants/Research Funding); MC2 Therapeutics – I(Grants/Research Funding); Pfizer Inc. – SP(H); Regeneron Pharmaceuticals, Inc. – A(H), SP(H); Sanofi – A(H), SP(H); Sonoma Pharmaceuticals – A(H); Sun Pharmaceutical Industries Ltd. – SP(H);
  • Van Voorhees, Abby S., MD: AbbVie – I(Grants/Research Funding); Celgene – A(H); Celgene Corporation – C(NC), I(Grants/Research Funding); Derm Tech International – C(H); Lilly ICOS LLC – C(NC), I(Grants/Research Funding); Merck & Co., Inc – O(OB); Novartis – C(NC); UCB – C(NC); WebMD – C(H);
  • Weinberg, Jeffrey M., MD: AbbVie – I(Grants/Research Funding), SP(H); Amgen – I(Grants/Research Funding), SP(H); Boehringer Ingelheim – I(Grants/Research Funding); Celgene Corporation – I(Grants/Research Funding), SP(H); Eli Lilly and Company – SP(H); Galderma Laboratories, L.P. – A(H), SP(H); Galderma Laboratories, LP – I(Grants/Research Funding); Janssen-Ortho Inc. – A(H); LEO Pharma, US – SP(H); Merck & Co., Inc. – A(H); Novartis – I(Grants/Research Funding), SP(H); Regeneron – I(Grants/Research Funding); Sandoz, a Novartis company – I(Grants/Research Funding); Valeant Pharmaceuticals International – SP(H); Warner Chilcott – SP(H);
Schedule
Friday, March 1
3:30 PM
Dr. Han / Are we in a post-PASI era in biologics?
3:50 PM
Dr. Weinberg / What's next? Update on The Biologic Pipeline
4:10 PM
Cohen / When not to use biologics
4:30 PM
Dr. Callis-Duffin / How psoriatic arthritis affects choice of biologics
4:50 PM
Dr. Van Voorhees / Navigating patient comorbidities to select an appropriate biologic
5:10 PM
Dr. Gordon / Putting it all together: My most challenging cases
Event Details
  • Date
    Friday, March 1
  • Time
    3:30 PM - 5:30 PM
  • Location
    Room 201
  • CME Credits
    2.00
  • Type
    New
Directors/Co-Directors
  • George Han, MD, PhD, FAAD
Speakers
  • Abby S. Van Voorhees, MD, FAAD
  • Jeffrey M. Weinberg, MD, FAAD
  • Kenneth B. Gordon, MD, FAAD
  • Kristina Patrice Callis-Duffin, MD, FAAD
  • Russell W. Cohen, MD, FAAD